Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
03 February 2016Website:
http://www.editasmedicine.comNext earnings report:
08 November 2024Last dividends:
N/ANext dividends:
N/APrice
regular market | 1 min agoDividend
Analysts recommendations
Institutional Ownership
EDIT Latest News
Editas Medicine (EDIT) came out with a quarterly loss of $0.75 per share versus the Zacks Consensus Estimate of a loss of $0.76. This compares to loss of $0.55 per share a year ago.
Editas (EDIT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Editas stock falls on a decision to seek a partner for its lead gene-therapy candidate, reni-cell, for SCD and TDT and focus resources on in vivo pipeline development.
Editas Medicine, Inc. (NASDAQ:EDIT ) Strategic Update Conference Call October 22, 2024 8:00 AM ET Company Participants Cristi Barnett - Corporate Communications and IR Gilmore O'Neill - Chief Executive Officer Linda Burkly - Chief Scientific Officer Erick Lucera - Chief Financial Officer Baisong Mei - Chief Medical Officer Caren Deardorf - Chief Commercial and Strategy Officer Conference Call Participants Samantha Semenkow - Citi Gena Wang - Barclays Jack Allen - Baird Yanan Zhu - Wells Fargo Soumit Roy - Jones Brian Cheng - JPMorgan Chase Joon Lee - Truist Dae Gon Ha - Stifel Alec Stranahan - Bank of America Rick Bienkowski - Cantor Phil Nadeau - TD Cowen Liisa Bayko - Evercore Mani Foroohar - Leerink Partners Timur Ivannikov - Raymond James Operator Good morning, everyone, and thank you for joining Editas Medicine's Strategic Update Webinar. This webinar is being recorded and can be accessed in the future through this same link or through the Investor section of the company's website.
Editas signs a license agreement with Genevant Sciences to develop novel mRNA-LNP gene editing therapeutics. Shares rise in after-hours trading.
CAMBRIDGE, Mass. and VANCOUVER, British Columbia and BASEL, Switzerland, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage gene editing company, and Genevant Sciences, a leading nucleic acid delivery company with world-class platforms and a robust lipid nanoparticle (LNP) patent portfolio, today announced that they have entered into a collaboration and nonexclusive license agreement to combine Editas Medicine's CRISPR Cas12a genome editing systems with Genevant's proprietary LNP technology in the development of in vivo gene editing medicines directed to two undisclosed targets in Editas' upregulation strategy.
CAMBRIDGE, Mass., Oct. 18, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage gene editing company, today announced that it will host a Company-sponsored webinar on Tuesday, October 22, 2024, at 8:00 a.m.
Shares of Editas Medicine, Inc. (EDIT, Financial), a biopharmaceutical company, experienced a notable drop of 5.18%. The stock is currently priced at $3.21 per share, with a trading volume of 976,255 shares and a turnover rate of 1.18%.
Editas Medicine, Inc. (NASDAQ:EDIT ) Chardan's 8th Annual Genetic Medicines Conference October 1, 2024 3:45 PM ET Company Participants Erick Lucera - CFO Cristi Barnett - VP Corporate Communications and IR Conference Call Participants Geulah Livshits - Chardan Geulah Livshits I'm Geulah Livshits, a biotech analyst at Chardan and it's my pleasure to introduce Erick Lucera, our CFO; and Cristi Barnett, VP Corporate Communications and IR at Editas. Thank you both for joining us today.
Editas Medicine has made significant progress in advancing reni-cel, their in-vivo editing pipeline, and business development, despite a 65% drop in stock price. Reni-cel shows promising clinical results for sickle cell disease and beta-thalassemia, with potential BLA submission by year-end, enhancing its risk-reward profile. Editas' in-vivo pipeline and strategic partnerships bolster its position, but competition and regulatory challenges remain significant risks.
What type of business is Editas Medicine?
Editas Medicine, Inc. is a pharmaceutical company based in Cambridge, Massachusetts, developing treatment methods based on CRISPR-Cas9 gene editing technology. Editas Medicine, Inc. was founded in 2013. Editas Medicine is a leading genome editing company at the clinical stage, working on the development of potentially transformative genomic medicines for a wide range of serious diseases. The company has developed its own genome editing platform based on CRISPR technology. Editas Medicine's main developments are in the field of eye diseases and engineered cell therapies for the treatment of hemoglobinopathies and cancer.
What sector is Editas Medicine in?
Editas Medicine is in the Healthcare sector
What industry is Editas Medicine in?
Editas Medicine is in the Biotechnology industry
What country is Editas Medicine from?
Editas Medicine is headquartered in United States
When did Editas Medicine go public?
Editas Medicine initial public offering (IPO) was on 03 February 2016
What is Editas Medicine website?
https://www.editasmedicine.com
Is Editas Medicine in the S&P 500?
No, Editas Medicine is not included in the S&P 500 index
Is Editas Medicine in the NASDAQ 100?
No, Editas Medicine is not included in the NASDAQ 100 index
Is Editas Medicine in the Dow Jones?
No, Editas Medicine is not included in the Dow Jones index
When was Editas Medicine the previous earnings report?
No data
When does Editas Medicine earnings report?
The next expected earnings date for Editas Medicine is 08 November 2024